Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)Jeremy S. Abramson,Aravind Ramakrishnan, Ana Alfonso Pierola, Ira Braunschweig, Guillaume Cartron, Catherine Thieblemont,Jose A. Pérez-Simón,Pere Barba,Peter A. Riedell,Carlos Solano,Thomas Gastinne,Alexandra LaCroce, Denise Thomas,Camille Poirot, Sarah Meadows,Kathryn J. Newhall,Daniel J. Lee,Mark G. Frattini, Emmanuel BachyBlood（2023）引用 0|浏览6暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
